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Abstract
Background: As negative regulators in Wnt signaling, Secreted Frizzled-Related Proteins (SFRPs)
are downregulated in a series of human cancers; and specifically, some matrix metalloproteinases
(MMPs), including MMP-2, MMP-7, MMP-9 and MT1-MMP, are frequently overexpressed in gastric
cancer. The aim of this study is to determine the expression status of SFRP5 in gastric cancer and
explore the correlation between both the expression of SFRP5 and that of these MMPs in this
cancer.
Methods: Expression of SFRP5, MMP-2, MMP-7, MMP-9 and MT1-MMP was determined by real-
time PCR, RT-PCR or Western blotting. The methylation status of SFRP5 was detected by
Methylation-specific PCR (MSP). Cell lines with SFRP5 methylation were demethylated by a DNA
methyltransferase inhibitor 5-Aza-2'-deoxycytidine (DAC). KatoIII cells were transfected with
pcDNA3.1 SFRP5 vector to strengthen SFRP5 expression. To abrogate SFRP5 expression in MKN1
cells, SFRP5 RNAi plamid was used to transfect them.
Results: SFRP5 expression was remarkably downregulated in 24 of 32 primary gastric cancer
specimens, and even was not detectable in 5 of 8 gastric cancer cell lines. MMP-7 and MT1-MMP
mRNA showed a stronger expression in these 24 specimens compared to the other 8 specimens.
They also showed higher levels in gastric cancer cell lines AGS and NCI-N87 which had no SFRP5
expression, compared to MKN1 with strong SFRP5 expression. However, they were significantly
downregulated, with SFRP5 expression restored in AGS and NCI-N87; and were considerably
upregulated with it abrogated in MKN1.
Conclusion: The results indicate there are frequent occurrences of downregualtion of SFRP5
expression in gastric cancer, primarily due to SFRP5 methylation. It seems to be responsible for the
upregulation of MMP-7 expression and MT1-MMP expression on the ground that they are inversely
correlated with SFRP5 expression.
Background
All the five secreted glycoproteins in Secreted Frizzled-
Related Protein (SFRP) family contain a cysteine-rich
domain (CRD) homologous to that of Wnt receptor Friz-
zled proteins. It is noted that via the CRD, they compete
with the Frizzled proteins for Wnt binding, interfering
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aberrant activation of the Wnt pathway and induce tum-
origenesis. SFRP1 is particularly well known for its fre-
quent downregulation in human tumors, mainly due to
hypermethylation of SFRP1 promoter [1-3]. Other mem-
bers of this family, such as SFRP2, SFRP4 and SFRP5 [4,5],
were also found to exert their roles in human cancers.
These studies have labeled SFRPs as the candidate tumor
suppressors in carcinogenesis.
It is also noted that matrix metalloproteinases (MMPs) are
involved in a variety of physiological and pathological
conditions, among which, their link with cancer has been
most extensively studied. As a family of zinc-dependent
endopeptidases, MMPs participate in the degradation of
extracellular matrix components. In addition, their spe-
cific substrates also include latent growth factors, growth
factor binding proteins, chemokines and cell adhesion
molecules. Naturally, MMPs are known not only for their
roles in invasion and metastasis of tumor, but also in
growth and angiogenesis of it. Overexpression of MMPs
has been observed in a series of cancers, with that of
MMP-2[6,7], MMP-7[8,9], MMP-9[10] and MT1-
MMP[11], in particular, typically present in gastric cancer.
Our initial finding showed that SFRP5 expression is signif-
icantly downregulated in gastric cancer, while the subse-
quent quantitative real-time PCR analysis revealed that
MMP-2, MMP-7, MMP-9 and MT1-MMP are all upregu-
lated in it. Such a finding that these MMPs are the targets
of Wnt signaling [12-15] led to our initial hypothesis:
there may be a link between downregulation of SFRP5
and overexpression of these MMPs in gastric cancer.
Another hypothesis was that the upregulation of these
MMPs may be related to aberrant activation of Wnt sign-
aling pathway due to SFRP5 downregulation.
Methods
Cell lines and tissue specimens
The human gastric cancer cell lines AGS, NCI-N87 and
KatoIII were obtained from the American Type Culture
Collection (Rockville, MD, USA); and MKN1, MKN28,
MKN45, SGC-7901 and HGC-27 were obtained from Key-
gen Biotech. Co. (Nanjing, China). These cell lines were
cultured in RPMI 1640 supplemented with 10% fetal
bovine serum, at 37°C in a humid incubator with 5%
CO2. 32 primary gastric cancer specimens and their corre-
sponding matched cancer adjacent normal tissue speci-
mens were obtained from patients under operation at
Shengjing hospital, Chinese Medical University. Informed
consent was obtained from all patients before collection
of the specimens, which were frozen in liquid nitrogen
immediately after surgical removal. Haematoxylin- and
eosin-staining sections were prepared for assessment of
the percentage of tumor cells, and only specimens with
>70% tumor cells were selected for analysis. This study
was carried out with the approval of the ethical committee
of China Medical University.
RT-PCR and real-time reverse-transcription PCR
Total RNA was isolated from tissues and cell lines by Tri-
zol (Takara, Dalian, China) according to the protocol sup-
plied by the manufacturers. cDNA was synthesized from 1
mg RNA using random 9 primer and AMV reverse tran-
scriptase. RT-PCR was performed using RNA PCR 3.0 Kit
(Takara, Dalian, China). Real-time PCR was performed
using the LightCycler system together with the LightCycler
DNA Master SYBR Green I Kit (LightCycler, Roche Diag-
nostics). The housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as an internal
control. Gene expression was quantified by the compara-
tive CT method, normalizing CT values to GAPDH and
calculating relative expression values. Primer sequences
for SFRP5, MMP-2, MMP-7, MMP-9, MT1-MMP and
GAPDH are shown in table 1.
Methylation-specific PCR and DNA demethylation
Genomic DNA was extracted from tissues and cell lines by
a standard phenol/chloroform extraction and ethanol
precipitation procedure. Methylation of SFRP5 was
detected by Genmed MSP Kit (Genmed, Shanghai,
China). The procedure was performed according to the
Table 1: Primer sequences for RT-PCR
Gene Sequence Product size Annealling temperature
MMP-2 Sense 5'-GGATGATGCCTTTGCTCG-3' 487 bp 55°C
Anti-sense 5'-ATAGGATGTGCCCTGGAA-3'
MMP-7 Sense 5'-CTTCAGGCAGAACATCCA-3' 220 bp 49°C
Anti-sense 5'-ATTTATTGACATCTACCCAC-3'
MMP-9 Sense 5'-AGGACGGCAATGCTGATC-3' 127 bp 58°C
Anti-sense 5'-TCGTAGTTGGCGGTGGTG-3'
MT1-MMP Sense 5'-CCTGCGTCCATCAACACT-3' 481 bp 57°C
Anti-sense 5'-TCACCTCCGTCTCCTCCTC-3'
SFRP5 Sense 5'-AGGGTAAGGGAAAGGTGGAG-3' 379 bp 60°C
Anti-sense 5'-GAGAAGCAGAGGCTGAGGAA-3'
GAPDH Sense 5'-GGGAAACTGTGGCGTGAT-3' 309 bp 56°C
Anti-sense 5'-AAAGGTGGAGGAGTGGGT-3'Page 2 of 10
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ated sequence and unmethylated sequence were described
in reference [4]. Cell lines with SFRP5 methylation were
demethylated by 5-Aza-2'-deoxycytidine (DAC) (2 mM,
Sigma, St Louis, MO, USA). Cells were seeded at a density
of 3 × 104 cells/cm2 in a 24 well plate on day 0, and
exposed to DAC on day 1, 2, and 3. After each treatment,
the cells were cultured in fresh medium. Control cells
were incubated without the addition of DAC. Cells were
harvested on day 4 for experiment.
Western blotting
Standard protocol was used. In brief, a total of 10 mg pro-
tein of each sample was run on a 12% sodium dodecyl
sulfate (SDS)/acrylamide gel. The proteins on acrylamide
gel were transferred to a nylon membrane, which was
blocked overnight (4°C in PBS with 0.1% Tween and 10%
milk powder). Polyclonal antibodies for SFRP5 (Santa
Cruz, CA, America), MMP-2, MMP-7, MMP-9 and MT1-
MMP (Abcam, Cambridge, United Kingdom), and the
corresponding secondary antibodies (Santa Cruz, CA,
America) were applied before immunoblotting. The
human gene b-actin (Santa Cruz, CA, America) was used
as an internal control.
RNA interference
SFRP5 RNAi plasmid and nonsilencing control RNAi plas-
mid were purchased from Takala Biotech. Co. (Dalian,
China). The target sequence of SFRP5 siRNA was 5'-
AAGAAGAATAAGGAGATGAAGTT-3', corresponding to
1022 to 1044 of the human SFRP5 cDNA sequence (Gen-
Bank: NM 003015). Cells were seeded into a 24-well plate
at a density of 2 × 105. On the following day cells were
transfected with SFRP5 siRNA or Control siRNA using
Lipofectamine 2000 (Invitrogen, Paisley, United King-
dom) according to the manufacturer's instructions.
Construction of expression plasmids and transient 
transfection
The full-length pcDNA3.1 (Invitrogen, Paisley, United
Kingdom) SFRP5 vector was made by cloning of the full-
length PCR product of SFRP5 with PFU DNA polymerase
(Invitrogen, Paisley, United Kingdom). All the plasmid
sequences were confirmed by DNA sequencing. For tran-
sient transfection experiments, cells were plated in a 24-
well plate at a density of 2 × 105 24 hours before transfec-
tion. Lipofectamine 2000 (Invitrogen, Paisley, United
Kingdom) was used to perform transfection with 2.0 mg
pcDNA3.1 SFRP5 vector or 2.0 mg pcDNA3.1 empty vector
(as control) according to the manufacturer's protocol.
Statistical analysis
c2 test was used to compare the methylation frequency
between tumors and tumor adajcent normal tissues. The
correlation between methylation and mRNA expression
in primary gastric cancer was analyzed by Fisher's exact
test. Mann-Whitney U-test was used to compare mRNA
expression between tumors and tumor adjcent normal tis-
sues. mRNA expression in gastric cell lines was compared
using Student's t-test or one way ANOVA. Statistical anal-
ysis was carried out using SPSS version 13.0 (SPSS, Chi-
cago, IL, USA). Difference was considered significant
when P-value was < 0.05.
Results
Downregulation of SFRP5 expression in primary gastric 
cancer specimens
Expression of SFRP5 mRNA was determined by real-time
reverse-transcription PCR in 32 gastric cancer specimens
and corresponding matched normal tissue specimens.
SFRP5 expression in each specimen was standardized to
GAPDH expression. As an attempt to compare the expres-
sion difference between tumors and normal tissues, we
normalized SFRP5 expression in tumors to the mean of
SFRP5 expression in matched normal group. The results
showed SFRP5 mRNA expression was downregulated by
more than 10-fold in 24 of 32 (75%) tumors compared to
normal tissues. In 4 of 32 (12.5%)tumors, there was a less
than 10-fold downregulation in expression level, and
SFRP5 expression was up-regulated in 4 of 32 (12.5%)
tumors (Table 2).
Next we performed methylation-specific PCR to detect the
methylation status of SFRP5 in the same cohort of tumors
and matched normal tissues. The detection reported
SFRP5 methylation in 22 (69%) of the 32 gastric cancer
specimens. In contrast, in 32 matched normal tissues,
only 5 (16%) was reported with SFRP5 methylation (c2 =
18.515, P < 0.001)(Figure 1). To further investigate the
role of promoter methylation in the downregulation of
SFRP5 expression in gastric cancer, we defined SFRP5
mRNA downregulation more than 10-fold as negative
expression, and SFRP5 mRNA downregulation less than
10-fold or SFRP5 mRNA upregulation as positive expres-
sion. The subsequent Fisher's exact test analysis showed
SFRP5 expression was correlated inversely with SFRP5
methylation (21/3 versus 1/7; P < 0.001).
Differential SFRP5 expression in gastric cancer cell lines
RT-PCR and Western blotting were used to examine SFRP5
expression in gastric cell lines MKN1, MKN28, MKN45,
KatoIII, AGS, NCI-N87, SGC-7901 and HGC-27, and the
examination showed SFRP5 expression varied in these cell
lines: a strong expression of it in MKN1, a weak but detecta-
ble one in KatoIII and SGC-7901, and none in MKN28,
MKN45, AGS, NCI-N87 and HGC-27 (Figure 2A, B).
To investigate whether SFRP5 expression was correlated
with SFRP5 methylation, methylation-specific PCR was
used to detect the SFRP5 methyaltion status in these gas-Page 3 of 10
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ylated in all 5 cell lines without SFRP5 expression
(MKN28, MKN45, AGS, NCI-N87 and HGC-27), and in
contrast, SFRP5 methyaltion was not found in MKN1,
KatoIII and SGC-7901 (Figure 2C, D). Next, with a DNA
methyltransferase inhibitor 5-Aza-2'-deoxycytidine
(DAC), we treated MKN28, MKN45, AGS, NCI-N87 and
HGC-27, where SFRP5 was methylated and silenced, and
interestingly, both SFRP5 mRNA and SFRP5 protein were
restored in all these 5 cell lines (Figure 2E, F).
Upregulation of expression of some MMPs in primary 
gastric cancer specimens
Real-time reverse-transcription PCR was performed to
determine the mRNA expression of some members in
MMP family, including MMP-2, MMP-7, MMP-9 and
MT1-MMP in 32 gastric cancer specimens and corre-
sponding matched normal tissue specimens. Further-
more, Mann-Whitney U-test was used to analyze the
difference of mRNA expression between these two groups.
The results showed that MMP-2, MMP-7, MMP-9 and
MT1-MMP were all significantly upregulated in gastric
cancer specimens compared to matched normal tissue
specimens (For both MMP-2 and MMP-9, P < 0.01; for
both MMP-7 and MT1-MMP, P < 0.001) (Figure 3A).
As for the correlation between expression of SFRP5 and
those of these MMPs, mRNA expression of these MMPs
was examined when we compared gastric cancer speci-
mens with negative SFRP5 expression to those with posi-
tive one. The study showed levels of MMP-7 mRNA and
MT1-MMP mRNA were significantly higher in the former
group than those in the latter group (P < 0.001, respec-
tively). However, such a difference was not found in
MMP-2 and MMP-9 (Figure 3B).
Differential expression of some MMPs in gastric cancer 
cell lines
We performed real-time reverse-transcription PCR and
Western blotting to determine the expression of MMP-2,
MMP-7, MMP-9 and MT1-MMP in gastric cell lines MKN1
(with strong SFRP1 expression), KatoIII (with weak SFRP1
expression), AGS and NCI-N87 (without SFRP1 expres-
sion). The results revealed that expression of these MMPs
varied in these cell lines (Figure 4A, B), and one way
ANOVA analysis showed both MMP-7 mRNA expression
and MT1-MMP mRNA expression were correlated
inversely with SFRP5 expression in these cell lines (P <
0.001, respectively). However, no significant correlation
was found between SFRP5 expression and MMP-2 expres-
sion or MMP-9 expression (Figure 4A).
Correlation between SFRP5 expression and MMP 
expression
To further explore the correlation between SFRP5 expres-
sion and MMP expression, first DAC was employed to
treat cell lines AGS and NCI-N87, where SFRP5 was meth-
ylated. The results showed that SFRP5 mRNA and SFRP5
protein were re-expressed in these two cells after the treat-
ment (Figure 2E, F). Then we examined the expression of
MMP-2, MMP-7, MMP-9 and MT1-MMP in these two cell
lines by real-time PCR and Western blotting (Figure 5A, B,
C); and the examination revealed that MMP-7 mRNA and
MT1-MMP mRNA in DAC-treated AGS were downregu-
lated compared to DAC-untreated AGS (P < 0.001, respec-
tively) (Figure 5A). Similar results were also found in cell
line NCI-N87 (P < 0.001, respectively) (Figure 5B).
Next, pcDNA3.1 SFRP5 vector was employed when
katoIII (with a low level expression of SFRP5) was trans-
fected, and pcDNA3.1 empty vector was employed in the
counterpart as control. The results showed that SFRP5
expression was elevated in KatoIII after the transfection in
the former case (Figure 6A, B). Subsequently the expres-
Table 2: SFRP5 expression and SFRP5 methylation in primary 
gastric cancer specimens.
No. Sex Age SFRP5 expression SFRP5 methylation
Cancer Normal
1 M 76 6 × 10-4 M U
2 M 65 8 × 10-4 M M
3 M 65 4 × 10-3 M U
4 F 67 4 × 10-3 M U
5 F 54 4 × 10-3 M U
6 M 81 6 × 10-3 M U
7 M 59 6 × 10-3 M U
8 M 47 7 × 10-3 M M
9 M 76 8 × 10-3 M U
10 F 68 9 × 10-3 U U
11 M 72 9 × 10-3 M U
12 F 76 9 × 10-3 M U
13 M 59 2 × 10-2 M M
14 M 77 2 × 10-2 M U
15 M 59 3 × 10-2 M U
16 F 70 4 × 10-2 U U
17 M 58 4 × 10-2 M U
18 M 64 4 × 10-2 M U
19 M 82 5 × 10-2 M U
20 F 49 6 × 10-2 M U
21 M 59 7 × 10-2 M M
22 F 44 8 × 10-2 M U
23 M 65 8 × 10-2 M U
24 M 74 9 × 10-2 U U
25 F 72 3 × 10-1 U U
26 F 60 5 × 10-1 U U
27 M 57 6 × 10-1 U U
28 M 71 6 × 10-1 U U
29 M 69 1.2 M M
30 M 68 1.4 U U
31 M 78 2.6 U U
32 M 66 5.7 U UPage 4 of 10
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Analysis of SFRP5 methylation in primary gastric cancer specimens (T) and matched normal tissue specimens (N) by Methyla-tion-specific PCRFigure 1
Analysis of SFRP5 methylation in primary gastric cancer specimens (T) and matched normal tissue specimens 
(N) by Methylation-specific PCR. Shown are representive results from specimen #2, #8, #10, #13, #16, #21, #24 and #29. 
M: methylated primers; U: unmethylated primers.
SFRP5 expression and SFRP5 methylation in gastric cancer cell linesFigure 2
SFRP5 expression and SFRP5 methylation in gastric cancer cell lines. (A) SFRP5 mRNA was not detected in MKN28, 
MKN45, AGS, NCI-N87 and HGC-27 by RT-PCR. (B) SFRP5 protein was not detected in MKN28, MKN45, AGS, NCI-N87 
and HGC-27 by Western blotting. (C) SFRP5 methylation was found in MKN28, MKN45, AGS, NCI-N87 and HGC-27 by 
methylation-specific PCR. (D) SFRP5 mRNA re-expression was found in MKN28, MKN45, AGS, NCI-N87 and HGC-27 after 
treatment with DAC by RT-PCR. (E) SFRP5 protein re-expression was found in MKN28, MKN45, AGS, NCI-N87 and HGC-
27 after treatment with DAC by Western blotting. M: methylated primers; U: unmethylated primers.
BMC Cancer 2009, 9:224 http://www.biomedcentral.com/1471-2407/9/224sion of MMP-2, MMP-7, MMP-9 and MT1-MMP in KatoIII
was detected by real-time PCR and Western blotting (Fig-
ure 6C, D). It is noted in the detection that, after transfec-
tion with pcDNA3.1 SFRP5 vector, both MMP-7 mRNA
and MT1-MMP mRNA were downregulated in KatoIII,
compared to control (P < 0.001, respectively) (Figure 6C).
Finally, SFRP5 RNAi plamid was used to transfect MKN1
(with strong SFRP5 expression), and correspondingly
nonsilencing RNAi plamid was employed in the counter-
part as control. It was observed that expression of SFRP5
was absent in MKN1 after transfection with SFRP5 RNAi
plasmid (Figure 7A, B). Then expression of MMP-2, MMP-
7, MMP-9 and MT1-MMP in MKN1 was detected by real-
time PCR and Western blotting (Figure 7C, D), and it was
noted in the detection that, after transfection with SFRP5
RNAi plamid, MMP-7 mRNA and MT1-MMP mRNA were
upregulated in MKN1, compared to control (P < 0.001,
respectively) (Figure 7C).
Discussion
Lots of studies have shown that aberrant Wnt signaling
pathway is involved in carcinogenesis, in fact, alterations
of downstream components in Wnt pathway have been
found in a series of human cancers. A case in point is the
association of mutations of APC with most of human
colon tumors [16]. In addition, b-catenin, another down-
stream component in Wnt pathway, is also frequently
mutated in intestinal cancers [16]. These mutations are
known to have led to the decreased degradation of b-cat-
enin before it is translocated and accumulated in the
nucleus. There, b-catenin interacts with T-cell factor/lym-
phocyte enhancer factor (TCF/LEF) to promote the tran-
scription of target genes in Wnt pathway. However, unlike
colon cancer, mutations in APC and b-catenin are quite
rare in gastric cancer, despite the occassional b-catenin
accumulation in it [17].
Interestingly, within Wnt pathway, the role of alterations
of upstream components in gastric carcinogenesis has
been drawing attention. The initial focus is the obvious
overexpression in certain members of Wnt family, such as
Wnt5a[18], Wnt8b[19], Wnt10a[20], and Wnt receptor
Frizzled 7[21]. Another spotlight is the hypermethylation
and downregulation of Wnt inhibitor SFRP1 in our recent
group report[22]. In addition, diminished expression of
SFRP2[23] and DKKs[24] (another Wnt inhibitor family)
was also observed. Both overexpression of Wnts or their
receptor Frizzled proteins, and downregulation of Wnt
inhibitors will lead to aberrant activation of Wnt pathway
and increase the transcription of Wnt target genes, such as
c-myc[25], cyclin D1[26] and some MMPs, which are
involved in initiation and progression of tumor. The focus
is then shifted onto the significant downregulation (>10-
fold) of SFRP5, another member of SFRP family, in 75%
of the total gastric cancer specimens, and no detectable
expression of it in 5 out of the total 8 gastric cell lines
tested. MSP analysis indicated a connection between the
absence of SFRP5 and its methylation in all these five cell
lines and 21 out of the 24 SFRP5-downregulated gastric
cancer specimens, for there is a resumption of it with these
cell lines demethylated by DAC. Taken together, these
results suggest a strong link between the common SFRP5
downregulation and its methylation in gastric cancer.
The assumption of a link between downregulation of
SFRP5 and upregulation of MMPS in gastric cancer is
based on the following findings. First, as a putative tumor
The mRNA expression of MMP-2, MMP-7, MMP-9 and MT1-MMP in primary ga tric cancer specimens by Real-time PCRFigure 3
The mRNA expression of MMP-2, MMP-7, MMP-9 
and MT1-MMP in primary gastric cancer specimens 
by Real-time PCR. (A) Gastric cancer specimen (T) 
expressed higher levels of MMP-2, MMP-7, MMP-9 and MT1-
MMP compared to matched normal tissue specimens (N). 
Data are expressed as mean ± SD, n = 32, *P < 0.01, **P < 
0.001, vs Normal. (B) SFRP5 expression-negative gastric can-
cer specimens (SFRP5-) expressed higher levels of MMP-7 
and MT1-MMP compared to SFRP5 expression-positive 
(SFRP5+) gastric cancer specimens. Data are expressed as 
mean ± SD, n = 24 and 8, respectively, **P < 0.001, vs 
SFRP5(+).Page 6 of 10
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human cancers, including gastric cancer; and in most
cases, it can lead to aberrant activation of Wnt signal path-
way. One recent study reported that cyclinD1 and c-myc,
both known as Wnt targer genes, were significantly down-
regulated, when the expression of SFRP5 was restored by
demethylation agent DAC after it was methylated in
breast cancer cell lines. Second, some MMPs, such as
MMP-2, MMP-7, MMP-9 and MT1-MMP, are frequenly
overexpressed in gastric cancers, primarily in both tumor
cells and stromal cells (except MMP-7, which is only
expressed in tumor cells). And levels of MMP-2 and MMP-
9 are also found elevated in plasma of gastric cancer
patients. Thus it is obvious that the overexpression of
these MMPs plays important roles in initiation and pro-
gression of gastric cancer. Third, other studies have shown
Wnt signals can upregulate many members of MMPs fam-
ily directly or indirectly, including MMP-1[27], MMP-
2[12,13], MMP-3[28], MMP-7[14], MMP-9[12,13], MMP-
13[13], MMP-26[29], MT1-MMP[15] and MT3-MMP[30].
In this study, real-time PCR was used to determine mRNA
levels of MMP-2, MMP-7, MMP-9 and MT1-MMP in gas-
tric cancers. We found these four MMPs were all upregu-
lated (from 1.4 folds to 4.2 folds). Next we analyzed the
correlation between downregualtion of SFRP5 and upreg-
ulation of these four MMPs. The first line of evidence
comes from the expression status of SFRP5 in primary gas-
tric cancers. Levels of MMP-7 and MT1-MMP were found
significantly high in the SFRP5-negative group. Second,
The expression of MMP-2, MMP-7, MMP-9 and MT1-MMP in gastric cancer cell lines MKN1, KatoIII, AGS and NCI-N87Figure 4
The expression of MMP-2, MMP-7, MMP-9 and MT1-MMP in gastric cancer cell lines MKN1, KatoIII, AGS and 
NCI-N87. (A) Differential mRNA expression of MMP-2, MMP-7, MMP-9 and MT1-MMP in MKN1, KatoIII, AGS and NCI-N87 
was found by real-time PCR. Data are expressed as mean ± SD, n = 3, *P < 0.05. (B) Differential protein expression of MMP-2, 
MMP-7, MMP-9 and MT1-MMP in MKN1, KatoIII, AGS and NCI-N87 was found by Western blotting.
The expression of MMP-2, MMP-7, MMP-9 and MT1-MMP in gastric cancer cell lines AGS and NCI-N87 after treatment with DACFigure 5
The expression of MMP-2, MMP-7, MMP-9 and MT1-MMP in gastric cancer cell lines AGS and NCI-N87 after 
treatment with DAC. (A) Real-time PCR analysis showed MMP-7 mRNA and MT1-MMP mRNA were downregulated in 
AGS after treatment with DAC. Data are expressed as mean ± SD, n = 3, *P < 0.001, vs DAC(-). (B) Real-time PCR analysis 
showed MMP-7 mRNA and MT1-MMP mRNA were downregulated in NCI-N87 after treatment with DAC. Data are 
expressed as mean ± SD, n = 3, *P < 0.001, vs DAC(-). (C) Weatern blotting analysis showed MMP-7 protein and MT1-MMP 
protein were downregulated in AGS and NCI-N87 after treatment with DAC.Page 7 of 10
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SFRP5 expression due to promoter hypermethyaltion,
presented high levels of MMP-7 and MT1-MMP; while cell
line MKN1 with strong expression of SFRP5 presented rel-
atively low levels of them. Third, when we restored SFRP5
expression with demethylation agent DAC in AGS and
NCI-N87, or enhanced SFRP5 expression with SFRP5
transfection in KatoIII, both MMP-7 expression and MT1-
MMP expression are found to have reduced significantly
in these cell lines. Finally, to further investigate the action
of SFRP5 downregulation on expression of MMPs, we
abrogated SFRP5 expression in MKN1 with SFRP5 RNAi.
Just as presumed, both MMP-7 expression and MT1-MMP
expression were significantly elevated. Taken together, all
the lines of evidence suggest a prevalence of SFRP5 down-
regulation in gastric cancer, which is responsible for the
upregulation of the expression of MMP-7 and MT1-MMP.
The mechanism involved in the upregulation of MMP-7
and MT1-MMP by SFRP5 downregulation may be pre-
sumably related to aberrant activation of Wnt signals.
Now it is well accepted that aberrant activation of Wnt sig-
naling pathway may induce carcinogenesis, and that these
Wnt-related tumors often have increased invasiveness and
metastasis, which is linked to some members in MMP
family. Studies have shown some putative TCF/LEF bind-
ing sites lie in the promoters of MMP-7[31], MT1-
MMP[32], MMP-2 and MMP-9[12], and via these binding
sites, Wnt/b-catenin can directly upregulate these MMPs.
For instance, it has been found that MMP-7 and MT1-
MMP are upregulated by b-catenin/LEF-TCF compound in
intestinal tumors [31,32]. Other researches showed Wnt
signals can upregulate MMP-2 and MMP-9 expression in T
cells and regulate T cell transmigration [12]. In addition,
Wnt/b-catenin can also upregulate MMP indirectly. Lowy
et al observed MT3-MMP was upregulated in gastric can-
cer, however, no functional TCF/LEF binding site was
found in the promoter of MT3-MMP[30]. Taken together,
it is clear that canonical Wnt signal pathway is involved in
the upregulation of these MMPs.
Our results did not show MMP-2 and MMP-9 were upreg-
ulated by SFRP5 downregualtion, though they were also
overexpressed in primary gastric cancers, and can be
Transfecting katoIII with pcDNA3.1 SFRP5 vectorFigur  6
Transfecting katoIII with pcDNA3.1 SFRP5 vector. (A) Increased expression of SFRP5 mRNA was detected in katoIII 
after SFRP5 transfection treatment by RT-PCR. (B) Increased expression of SFRP5 protein was detected after SFRP5 transfec-
tion treatment by Western blotting. (C) Real-time PCR analysis showed MMP-7 mRNA and MT1-MMP mRNA were downreg-
ulated in katoIII after SFRP5 transfection treatment. Data are expressed as mean ± SD, n = 3, *P < 0.001, vs Empty vector. (D) 
Weatern blotting analysis showed MMP-7 protein and MT1-MMP protein were downregulated in katoIII after SFRP5 transfec-
tion treatment.Page 8 of 10
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study, breast cancers induced by Wnt-1 overexpressed a
series of MMPs, including MMP-2 and MMP-9, except
MMP-7 [13], a long held Wnt target gene in intestinal
tumors. These studies suggest that Wnt target genes may
be tissue-specific, though it is true that the regulation of
MMP expression is complex and it is certain that Wnt sig-
naling is not alone among numerous factors, such as TNF-
a [33], H. pylori [34] in regulating MMP expression in gas-
tric cancer.
It should be noted that downregulation of SFRPs seems to
be involved in carcinogenesis via both canonical Wnt
pathway and noncanonical Wnt pathway. One recent
study has demonstrated SFRP1 can inhibit the canonical
Wnt/b-catenin pathway in breast cancer cells[35]. Inter-
estingly, in b-catenin-deficient human mesothelioma cell
lines, SFRP4 can still inhibit cell growth and promote
apoptosis[36]. Another studies showed noncanonical
Wnt pathway is also involved in the regulation of MMPs.
For instance, Wnt5a has been found to upregulate MMP1
in endothelial cells[27] and MMP-3 in mouse mammary
cells[30]. Therefore up to now, we can not rule out the
possibility that SFRP5 downregulation upregulates MMP-
7 and MT1-MMP via noncanonical Wnt pathway.
Conclusion
The results indicate there are frequent occurrences of
downregualtion of SFRP5 expression in gastric cancer, pri-
marily due to SFRP5 methylation. It seems to be responsi-
ble for the upregulation of MMP-7 expression and MT1-
MMP expression on the ground that they are inversely cor-
related with SFRP5 expression.
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Silencing SFRP5 by RNAi in MKN1 cellsFigure 7
Silencing SFRP5 by RNAi in MKN1 cells. (A) SFRP5 mRNA was not detected in MKN1 after SFRP5 RNAi treatment by 
RT-PCR. (B) SFRP5 protein was not detected in MKN1 after SFRP5 RNAi treatment by Western blotting. (C) Real-time PCR 
analysis showed MMP-7 mRNA and MT1-MMP mRNA were upregulated in MKN1 after transfection with SFRP5 RNAi plamid. 
Data are expressed as mean ± SD, n = 3, *P < 0.001, vs Control RNAi. (D) Weatern blotting analysis showed MMP-7 protein 
and MT1-MMP protein were upregulated in MKN1 after transfection with SFRP5 RNAi plamid.Page 9 of 10
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